ADMA Biologics Reports Third Quarter 2026 Financial Results

ADMA Biologics reported third-quarter 2026 revenue of $141.1 million, above the FactSet estimate of $138.1 million. Adjusted earnings per share were $0.23, exceeding the $0.20 consensus estimate. The company said the results reflect ongoing commercial performance in its specialty plasma-derived biologics business.